We are live on ! Find out more
NBP

NovaBridge Biosciences American Depositary Shares

80 hedge funds and large institutions have $1.13B invested in NovaBridge Biosciences American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,007% more call options, than puts

Call options by funds: $295K | Put options by funds: $14K

136% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 11

125% more funds holding in top 10

Funds holding in top 10: 49 (+5)

100% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 15

84% more capital invested

Capital invested by funds: $616M → $1.13B (+$515M)

23% more funds holding

Funds holding: 6580 (+15)

6.04% more ownership

Funds ownership: 8.06%14.09% (+6%)

Holders
80
Holders Change
+15
Holders Change %
+23.08%
% of All Funds
1.4%
Holding in Top 10
9
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+125%
% of All Funds
0.16%
New
26
Increased
30
Reduced
15
Closed
11
Calls
$295K
Puts
$14K
Net Calls
+$281K
Net Calls Change
+$281K
Name Holding Trade Value Shares
Change
Change in
Stake
MS
51
Maven Securities
Jersey
$1M -$1.26M -23,136 -52%
Voloridge Investment Management
52
Voloridge Investment Management
Florida
$932K +$1.04M +19,223 New
O
53
OrbiMed
New York
$900K -$31.9M -587,505 -97%
State Street
54
State Street
Massachusetts
$852K +$125K +2,295 +15%
Invesco
55
Invesco
Georgia
$774K +$129K +2,376 +17%
SCM
56
Sio Capital Management
New York
$727K
HSBC Holdings
57
HSBC Holdings
United Kingdom
$649K -$6.78K -125 -0.9%
NSRI
58
New Silk Road Investment
Singapore
$582K
CSS
59
Cubist Systematic Strategies
Connecticut
$579K +$648K +11,942 New
Geode Capital Management
60
Geode Capital Management
Massachusetts
$508K
SFI
61
Susquehanna Fundamental Investments
Pennsylvania
$463K
Man Group
62
Man Group
United Kingdom
$402K +$450K +8,297 New
VEA
63
Virtus ETF Advisers
New York
$381K +$7.32K +135 +2%
SG Americas Securities
64
SG Americas Securities
New York
$322K +$60.1K +1,108 +20%
Citadel Advisors
65
Citadel Advisors
Florida
$249K -$3.9M -71,847 -93%
DekaBank Deutsche Girozentrale
66
DekaBank Deutsche Girozentrale
Germany
$227K
ED
67
Exane Derivatives
France
$182K +$204K +3,764 New
Royal Bank of Canada
68
Royal Bank of Canada
Ontario, Canada
$79K
LSA
69
Leonteq Securities AG
Switzerland
$78.1K -$129K -2,387 -60%
Zurich Cantonal Bank
70
Zurich Cantonal Bank
Switzerland
$56K +$62.3K +1,149 New
TRCT
71
Tower Research Capital (TRC)
New York
$34K +$26.3K +485 +226%
UBS Group
72
UBS Group
Switzerland
$32K +$3.47K +64 +11%
IA
73
IFP Advisors
Florida
$24K -$760 -14 -3%
PCM
74
Penserra Capital Management
California
$20K +$3.25K +60 +17%
KFA
75
Krane Funds Advisors
New York
$10K

NBP Hedge Fund Activity: Q1 2021 in Review

80 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in NovaBridge Biosciences American Depositary Shares (NBP) for Q1 2021, worth a combined $1.13B — up 84% from $616M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NBP positions and 11 closed out — a net gain of 15 holders — while 30 added to existing stakes and 15 trimmed.

The largest buyer was HHLR Advisors, adding an estimated $278M. The largest seller was OrbiMed, cutting an estimated $31.9M.

  • 80 institutional investors held NovaBridge Biosciences American Depositary Shares (NBP) as of Q1 2021, up from 65 in Q4 2020.
  • Funds reported $1.13B of NovaBridge Biosciences American Depositary Shares stock for Q1 2021, up 84% quarter-over-quarter.
  • 26 funds opened new NovaBridge Biosciences American Depositary Shares positions in Q1 2021 and 11 closed out, a net change of +15 holders.
  • The largest NovaBridge Biosciences American Depositary Shares buyer in Q1 2021 was HHLR Advisors, an estimated $278M added.
  • The largest NovaBridge Biosciences American Depositary Shares seller in Q1 2021 was OrbiMed, an estimated $31.9M sold.

Based on aggregated 13F filings for Q1 2021.